Groundbreaking innovation for the diagnosis and treatment of Long COVID
people worldwide living with Long COVID.
people in the United States living with Long COVID.
of clinical trials are developing a therapy.
estimated economic cost worldwide, every year.
Economic cost: Davis HE et al., Long COVID: major findings, mechanisms and recommendations, Nature Medicine, 2024.
Long COVID is an insidious, debilitating multi-organ condition that can compromise physical and mental well-being for months to years. The U.S. Department of Health and Human Services has declared it a national health priority.
No treatment is approved. Without a diagnostic biomarker, the disease is broadly defined, which makes targeted treatment difficult. Current vaccines and antivirals do not clear persistent SARS-CoV-2 reservoirs or restore functional T cell immunity.
T cell dysfunction has been identified as a unifying characteristic of Long COVID: the T cells that should clear persistent virus have become exhausted. TI-101, an investigational T cell immunotherapy, is designed to restore them, aimed at three conserved viral proteins that do not mutate the way spike does.
Both sides of the problem: a T cell diagnostic, TI-103, to identify patients and measure benefit, and TI-101, designed to target the root cause by clearing persistent virus reservoirs. The TI-101 IND filing is targeted for the first quarter of 2027.
Leaders who have taken vaccines and medicines from the lab to approval, from MedImmune, Novavax and Operation Warp Speed to Allergan, Merck, Novartis, GSK and the CDC.
An issued U.S. patent covering TI-101's composition, with a priority date of April 2020, under an exclusive worldwide license from the University of California.
Long COVID patients show dysfunctional T cells, and in a humanized mouse model of Long COVID, TI-101 reduced virus in tissue 100 to 1,000 fold. Animal data; TI-101 has not yet been tested in humans.
Founded on UC Irvine science, supported by an NIH/NIAID SBIR grant, and engaged early and proactively with the FDA.
TechImmune, Inc. was founded in 2021 around the T cell technology platform exclusively licensed from the University of California, Irvine, with the mission to develop novel strategies against coronaviruses to protect the public and economic health of individuals and societies globally.
Our approach is uniquely designed to target the root cause of disease by restoring functional anti-viral immunity, with the potential to deliver the first approved therapeutic intervention for Long COVID.
Explore MoreRecent reporting on the disease TechImmune is working to address, from independent publishers. Links open the original source.
A spinout of the Gavin S. Herbert Eye Institute, holding an exclusive license to a trio of coronavirus patents developed in the Laboratory of Cellular & Molecular Immunology.
Federal SBIR support for development of a universal vaccine against multiple coronavirus variants of concern, alongside private equity and philanthropic funding.
A seasoned team with a track record across Novavax, MedImmune, Allergan, Novartis and GSK Vaccines. Collectively, our officers and board members have launched dozens of companies and brought multiple healthcare products to market.
TechImmune is developing a first-in-class T cell-based immunotherapy that targets the root cause of Long COVID by clearing persistent SARS-CoV-2 reservoirs and restoring functional anti-viral immunity, with the potential to deliver the first disease-modifying treatment for Long COVID.
Unlike acute COVID-19 infections, Long COVID cannot be fully addressed with current vaccines or existing antiviral therapies, which do not clear persistent SARS-CoV-2 reservoirs or restore functional T cell immunity. TechImmune's immunotherapy focuses on conserved non-spike viral antigens, boosting protective T cell responses to clear those reservoirs and address the underlying cause rather than just the symptoms.
TechImmune was founded in 2021 around a T cell technology platform exclusively licensed from the University of California, Irvine, where it was invented by Professor L’bachir BenMohamed, PhD. The company holds an exclusive license agreement that includes patents in the United States.
More than 420 million people worldwide are living with Long COVID, including more than 12 million in the United States, with 3 to 3.5 million projected to seek treatment for moderate to severe disease. Only a handful of clinical trials are developing a therapy, and the estimated economic cost worldwide is $1 trillion every year.
TechImmune is a preclinical-stage biotechnology company advancing its lead Long COVID immunotherapy, TI-101, through IND-enabling studies toward an IND filing in the first quarter of 2027. The company is also developing TI-100, a broad spectrum coronavirus vaccine supported by an NIH/NIAID SBIR grant.
TechImmune is advancing toward IND-enabling studies and first-in-human trials and welcomes investment, partnering and scientific inquiries. The company can be reached by phone at +1 (949) 691-4350, by email at contact@techimmune.com, and at 5270 California Avenue, Suite 300, Irvine, CA 92617.
TechImmune is advancing toward IND-enabling studies and first-in-human trials. For investment, partnering and scientific inquiries, reach out below.
